Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GILEAD SCIENCES, INC. Director's Dealing 2015

Feb 19, 2015

29828_dirs_2015-02-19_6dc7792b-0813-4b92-b56b-602fab9f0db3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GILEAD SCIENCES INC (GILD)
CIK: 0000882095
Period of Report: 2015-02-13

Reporting Person: BISCHOFBERGER NORBERT W (EVP, R&D and CSO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2015-02-13 Common Stock A 248 $85.6120 Acquired 119550 Direct
2015-02-17 Common Stock A 22440 Acquired 141990 Direct
2015-02-17 Common Stock A 106668 Acquired 248658 Direct
2015-02-17 Common Stock F 83490 $103.84 Disposed 165168 Direct

Footnotes

F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.

F2: Represents shares of the Issuer's common stock subject to specific tranches of performance share awards made to the Reporting Person on February 1, 2013, and February 1, 2014. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2015 and December 31, 2016, respectively.

F3: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on January 26, 2012. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors.